Polyphenols have been extensively studied for their antioxidant and anti-inflammatory properties. Recently, their antiglycative actions by oxidative stress modulation have been linked to the prevention of diabetes and associated complications. This article assesses the evidence for polyphenol interventions on glycohemoglobin (HbA1c) in non-diabetic, pre-diabetic, and type 2 diabetes mellitus (T2DM) subjects. A systematic review of polyphenols' clinical trials on HbA1c in humans was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis. Thirty-six controlled randomized trials with HbA1c values were included. Polyphenols (extracts, supplements, and foods) were supplemented (28 mg to 1.5 g) for 0.7 to 12 months. Combining all subjects (n D 1954, mean baseline HbA1c D 7.03%, 53 mmol/mol), polyphenol supplementation significantly (P < 0.001) lowered HbA1c% by -0.53 § 0.12 units (-5.79 § 0.13 mmol/mol). This reduction was significant (P < 0.001) in T2DM subjects, specifically (n D 1426, mean baseline HbA1c D 7.44%, 58 mmol/mol), with HbA1c% lowered by -0.21 § 0.04 units (-2.29 § 0.4 mmol/mol). Polyphenol supplementation had no significant effect (P > 0.21) in the nondiabetic (n D 258, mean baseline HbA1c D 5.47%, 36 mmol/mol) and the pre-diabetic subjects (n D 270, mean baseline HbA1c D 6.06%, 43 mmol/mol) strata: -0.39 § 0.27 HbA1c% units (-4.3 § 0.3 mmol/mol), and -0.38 § 0.31 units (-4.2 § 0.31 mmol/mol), respectively. In conclusion, polyphenols can successfully reduce HbA1c in T2DM without any intervention at glycemia, and could contribute to the prevention of diabetes complications.
Introduction
Hyperglycemia is clearly recognized as the primary factor in the onset and progression of diabetes. Both acute and chronic hyperglycemia enhance the formation of early, intermediate, and advanced glycation end products (AGEs), leading to a series of pathogenic complications (Jaku s et al., 2004) . AGEs are complex, heterogeneous, and chemically stable, which progressively accumulate on the tissue and organs, developing chronic complications of diabetes, such as retinopathy, nephropathy, neuropathy, micro-and macro-vasculopathies (Jaku s et al., 2004) . Glycohemoglobin (HbA1c) is an early glycation product and a marker of chronic glycemia from the preceding two to three months (Singh et al., 2001; American Diabetes Association, 2012) . HbA1c correlates with both micro-and macro-vascular complications and is considered as the standard biomarker for glycemic management (American Diabetes Association, 2012) .
Conceding that glycated products are involved in the pathogenesis of diabetes, anti-glycation treatments may assist in the prevention of diabetes and their complications. Nutritional interventions, especially those involving plant foods and beverages or specific phytochemicals, have attracted attention for the management of diabetes and its complications. Polyphenols are one of these major classes of phytochemicals. Ubiquitous in plant foods, they have a wide range of chemical structures usually comprising at least one aromatic ring with hydroxyl groups (Crozier et al., 2009; Xie et al., 2013) . This wide structural variation, including their substituents, has given to polyphenols their different levels of anti-AGEs and anti-diabetic activities demonstrated in vivo and in vitro studies (Klein et al., 2011b; Xie et al., 2013) . While the original paradigm indicated the anti-glycative effect of polyphenols was due to their free radical scavenging potential, new evidence of scavenging-independent protection has emerged (Mandeville et al., 2009; Vlassopoulos et al., 2013; Sadowska-Bartosz et al., 2014) .
HbA1c has a higher positive predictive value to identify people at risk of diabetes and cardiovascular complications. Hence, concentrations in the range of 5.5 to 6% are appropriate to initiate preventive interventions (American Diabetes Association, 2012) . Nutrition is a potential tool in regulating glucose metabolism, and it has been reported that dietary polyphenol might be protective (Hanhineva et al., 2010) . There are several studies and reviews addressing the beneficial effects of polyphenols on humans and animals as well as in vitro models on the glycemic control and cardiovascular risk factors in patients with diabetes (Biesalski, 2007; Chuang et al., 2011; Overman et al., 2011; Rosenow et al., 2012) . However, the results of human clinical trials investigating the effects of polyphenols on glycation have presented inconsistent results, with some of them presenting short intervention periods that cannot reflect any change during this timeframe. Therefore, the present systematic review aimed to evaluate the current published randomized controlled trials related to polyphenol supplementation on HbA1c concentrations in non-diabetic, pre-diabetic, and type 2 diabetes mellitus (T2DM) subjects.
Methods
The present systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline (Moher et al., 2009) . A literature research was carried out on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and ISI Web of Knowledge for randomized clinical trials that examined the effects of polyphenols on glycohemoglobin conducted in human subjects. The database search included all studies published before February 2014. The following search terms were used to identify relevant studies: phenol, polyphenol, phytoestrogen, resveratrol, ellagitan, elligitan, catechin, flavan, flavon, fruit, vegetable, spice, tea, cocoa, coffee, or juice, which were paired with treatment, intervention, or supplementation. The terms glycation, glycated, hemoglobin, HbA1c, or glycohemoglobin were used as well. The wild-card term "Ã" was used to improve the sensitivity of the search by increasing the number of matches. The references of all relevant trials and reviews were hand-searched for additional studies.
Study selection
Studies were chosen for analysis if they met the following criteria:
(1) The systematic review was restricted to the reports of clinical trials conducted in non-diabetic, pre-diabetic, and diabetic subjects without any diabetic complications; (2) the articles were published in English or the abstracts were available in English; (3) studies were controlled parallel or cross-over randomized trials supplemented with polyphenols in the form of supplements (oral capsules, extracts, and powders), or specific foods and beverages; (4) the baseline and endpoint of glycohemoglobin values or their differences were available with standard deviations (SDs), standard errors (SEs), or 95% Confidence Intervals (CIs); and (5) a concurrent control group was included for the polyphenol group, where the only difference between them was the polyphenol supplementation. Studies were excluded when polyphenols were given as part of multicomponent treatment. When data were insufficient, the authors were contacted to obtain additional study details and confirm their eligibility.
Data extraction and quality assessment
Search, data collection, and quality assessment were carried out independently by two reviewers, divided into non-diabetics (including pre-diabetic trials), and T2DM trials according to the inclusion criteria. Title and abstracts were inspected for potential inclusion, and duplicates were removed. Full-text articles were attained for further screening of suitability, and reference lists were screened for inclusion. Data on treatment, study design, subjects' characteristics, number of participants, year of publication, period of intervention, and effect of intervention on glycation were extracted from all the acquired articles. All the authors reviewed the collected data before conducting the statistical analyses. For any discrepancy between them, a discussion was held until a consensus was reached. If HbA1c values were reported multiple times in different stage during the trial, only final values were included in the metaanalysis. In addition, all HbA1c concentrations were dually reported in percentage and mmol/mol. HbA1c concentrations were converted between National Glycohemoglobin Standardization Program (NGSP) values in percentage and International Federation of Clinical Chemistry (IFCC) values in mmol/mol using the following equation:
NGSP D .0:09148 £ IFCCÞ C 2:152/:
The quality of the included articles was estimated using the following criteria: (1) randomization, (2) minimal risk of bias during patient allocation, (3) blinding, (4) report of the number of withdrawals and explanation for withdrawal, (5) comparability of control and polyphenol supplemented group at baseline, (6) intention-to-treat analysis, and (7) a clearly described intervention procedure (Higgins, 2008) . Authors (Susana A. Palma-Duran and Antonis Vlassopoulos) scored the articles, attributing one point for each criteria addressed in the study design, toward a possible score of 0 (lowest quality) to 7 (highest quality). Studies receiving a score 5 were deemed to be of high quality, whereas those with a score <5 were considered of low quality.
Statistical analysis
The meta-analysis was performed using NCSS 2007 version: 07.1.20, 2010 (Hintze, J. 2009 and Comprehensive Meta-Analysis (Biostat Inc, 2009, Englewood USA). Studies were stratified according to health status as nondiabetic, pre-diabetic, and T2DM for analysis. Diabetes mellitus and other categories' classification was established according to the report of World Health Organization (WHO) consultation; Diagnosis and Classification of Diabetes Mellitus; and use of glycated hemoglobin in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation (1999, 2011) . HbA1c was presented as percentage at baseline and at the end of polyphenol supplementation. When not directly available, SDs were calculated from SEs or 95% CIs. To avoid double counting of subjects, and unit-of-analysis error, the control group, in trials with more than one treatment arm, was divided according to the number of subgroups within the trial. Metaanalysis was performed using a correlation coefficient (R) D 0.5 between groups to allow the calculation of variance used to weigh each study and estimate the variance of combined effects, as described by Follmann et al. (1992) . Differences in mean § SE were calculated for net differences in HbA1c%, presented along 95% CIs, with equivalence for the net change in mmol/mol § SE. The effect of heterogeneity of treatment between studies was tested using the Cochran's Q test (studyby-treatment interaction, P < 0.1). In addition, the I 2 statistic was also examined; I 2 > 50% was considered as an indicator of heterogeneity among trials. A random-effects model was used if a significant heterogeneity was presented. The results of meta-analysis were explained by the forest plot of the mean difference (95% CI). Moreover, to evaluate the influence of each study on the effect size (ES), a sensitivity analysis was accomplished using the one-study remove approach. To examine potential publication bias, the Egger regression test and funnel plots were assessed. Following the meta-analysis, the pooled effect size was calculated using the following equation:
Results

Study selection
The flow diagram of the identification process for eligible studies is shown in Figure 1 . Initially, 926 potential eligible studies were identified through PubMed and Web of Knowledge. After exclusion of non-clinical trials, publications not written in English or irrelevant to the purpose of the review, 83 articles were assessed for full-text eligibility. After full-text review, 36 randomized control trials (RCT) were excluded due to lack of HbA1c measurement, HbA1c measurement not reported, only HbA1c baseline concentrations reported, HbA1c measurements not published despite measurement, authors not replying to emails, or polyphenols provided as part of a multicomponent treatment. Finally, 36 studies were selected for inclusion in the systematic review.
Study characteristics
The identified trials were divided as non-diabetic, pre-diabetic, and T2DM. The characteristics of the trials are shown in Tables 1, 2, and 3 for non-diabetic, pre-diabetic, and T2DM, respectably. A total of 1954 subjects were included in our study; 528 non-diabetics and 1426 T2DM. Some trials included nondiabetic and T2DM subjects and these studies were divided for the analysis. HbA1c concentrations for each stratum are presented in Table 4 in percentage and mmol/mol. A variety of polyphenols were given, more often as extracts or powders, obtained from polyphenol-rich foods and offered as capsules for ingestion (n D 27 studies). The principal sources of polyphenols were green tea, juice, cinnamon, and chocolate bar. The total amount of polyphenol supplement given ranged from 28 mg to 1.5 g per day. The intervention studies lasted from under one month to one year, with three months the Figure 1 . Flow diagram of the study selection process. most common duration. Most studies (20 out of 36) were double blind trials. The trials varied in size from 18 to 95 subjects for non-diabetic, 19 to 123 subjects for pre-diabetic, and from 12 to 114 subjects for T2DM interventions. Study settings were diverse, with 15 studies from Asia, nine from the United States, eight from Europe, and four from elsewhere (Australia, Brazil, Canada, and Mauritius). Subjects in the T2DM trial group were conventionally medicated, most of them with metformin, while non-diabetic subject were not medicated.
Data quality
Study quality was evaluated for all trials and the results are presented in Tables 1, 2, and 3. Most trials (n D 32) were classified as high quality (5), with only four trials classified as low quality (<5). High quality trials presented adequate minimal risk of bias during patient selection and reported use of random allocation number for the subjects. Details regarding withdrawals were reported in 28 trials. Only three trials analyzed data according to the intention-to-treat principle, achieving the highest score of 7.
Effect of polyphenol intake on HbA1c
Results of polyphenol supplementation on HbA1c% reduction are presented in the Forest plot in Figures 2-4 (difference in mean value and 95% CI) according to health status. The metaanalysis of polyphenol intervention on the population as a whole (all three strata) significantly lowered HbA1c%: -0.53 § 0.12, 95% CI: -0.77 to -0.29 units HbA1c% (-5.79 § 1.3 mmol/mol, 95% CI: -8.4 to -3.2), compared with the control group (P < 0.001, effect size D 0.09).
Looking into individual strata (Fig. 2) , polyphenol treatment showed a favorable reduction of HbA1c concentrations in the supplemented T2DM subjects compared with the control subjects: ¡0.21 § 0.04, 95% CI: ¡0.29 to ¡0.121 units HbA1c% (¡2.29 § 0.4 mmol/mol HbA1c, 95% CI -3.2 to 1.3, P < 0.001). Contrarily, polyphenols treatment in non-diabetic subjects (Fig. 3) did not lead to significant (P D 0.15) reduction D 0.09) . A significant heterogeneity was found for the changes in HbA1c% for non-diabetic and pre-diabetic trials (P < 0.001, I 2 D 97.5% and 93.2% respectively) and the results are reported with the random-effects model. There was no significant heterogeneity for the T2DM group (P D 0.28; I 2 D 10.89), in this case, the results are reported based on the fixed-effects model. The funnel plots for each group approximated an inverted symmetrical funnel, which suggests limited publication bias (Fig. 5 ). Using the Egger regression test, publication bias was found in the combined meta-analyses for all strata (b0 D ¡2.80, P D 0.003), indicating that the smaller trials show a more pronounced effect than the larger ones. This was the case for the T2DM stratum, which presented a statistically significant asymmetry (b0 D ¡0.647, P < 0.01), but not the non-diabetic trials (b0 D 5.37, P D 0.08) or the pre-diabetic trials (b0 D 1.46, P D 0.37).
Sensitivity analysis to explore heterogeneity was performed using the one-study remove approach. We found no significant change in HbA1c% reduction between treatment groups in each stratum. Similarly, analysis limited to high-quality studies (score 5) was performed on the T2DM stratum (where no heterogeneity existed) to determine risk of bias due to poorer quality studies (eliminated trials are listed in Table 3 ). HbA1c% reduction was still significant when analyses were limited to high quality studies (n D 25) and was not changed: ¡0.27 § 0.06 units HbA1c%, 95% CI: ¡0.39 to ¡0.16 (3.0 § 0.7 mmol/mol HbA1c, 95% CI: ¡4.3 to ¡1.7, P < 0.001). This was not performed for the pre-diabetic and non-diabetic strata since few trials (n D 8) with a high quality level (except for Banini et al., 2006) were found.
In addition, when analysis was restricted to longer trials (6 and 12 weeks) on all three stratums combined, reduction in HbA1c became more marked. Including trials lasting six weeks or longer led to a reduction of ¡0.40 § 0.09 units HbA1c%; 95% CI: ¡0.57 to ¡0.22 (¡4.4 § 1.0 mmol/mol, 95% CI: ¡0.57 to ¡2.4, P < 0.001). Trials lasting 12 weeks or longer led to a reduction of ¡0.38 § 0.10 units HbA1c%; 95% CI: ¡0.59 to ¡0.18 (¡4.2 § 1.1 mmol/mol, 95% CI: ¡6.4 to ¡2.0, P < 0.001). The same was for the T2DM stratum lasting for 12 weeks or longer with a reduction of ¡0.27 § 0.07 units HbA1c%; 95% CI: ¡0.40 to ¡0.14 (3.0 § 0.8 mmol/mol; 95% CI: ¡4.4 to ¡1.5, P < 0.001).
Discussion
Glycated tissue components are recognized as markers of vascular complications in diabetic as well as non-diabetic subjects (Selvin et al., 2010b) . As a widely used example, HbA1c during the first three months after T2DM diagnosis is a strong determinant of cardiovascular death within five years and can predict microvascular and macrovascular diseases (Mulnier et al., 2006; Kerr et al., 2011) . Fructosamine concentrations have also been associated with cardiovascular mortality (Browner et al., 1999; Mittman et al., 2010) . Thereby, lowering glycated concentrations after diagnosis may reduce long-term risks of diabetes complication.
Our meta-analysis showed a significant ¡0.53 § 0.12 unit reduction in HbA1c% in the total population (n D 1954) irrespective of diabetes status (equivalent to ¡5.8 § 1.3 mmol/mol), which was sustained among the T2DM individuals (n D 1426) but not significant among the pre-diabetic and non-diabetic subjects, whose baseline HbA1c was lower.
The ARIC study showed that for every one unit increase in HbA1c% being associated with a 55% risk of stroke (Selvin et al., 2010a) . Overall, the EPIC, ARIC, and AusDiab studies suggested a 18-26% increase in all-cause mortality for each 1% increase in HbA1c (Khaw et al., 2004; Barr et al., 2009; Selvin et al., 2010a) . Assuming a linear association between HbA1c increase and risk of comorbidities, a reduction of 0.53 units in HbA1c%, as seen in all subjects combined, could result in 14-23% reduction in all-cause mortality and 26% decrease in the risk of stroke. In spite of the relatively small effect size of the treatment (0.09 for all strata), there is the potential for sizeable clinical and public health significance. As most of polyphenol studies are short intervention trials, consequently long-term clinical outcomes have not been measured yet.
Our results are in concordance with a previous meta-analysis assessing cinnamon intake on HbA1c (Davis et al., 2011) . The six cinnamon trials included by Davis et al. (2011) (n D 435 subjects) led to a significant decrease in mean HbA1c (0.09%; 95% CI: 0.04 to 0.14). Another meta-analysis (six trials, <3 months, n D 348 subjects) (Zheng et al., 2013) quantifying the effect of green tea catechins on glycemic control failed to observe a significant decrease in HbA1c (¡0.04%; 95% CI: ¡0.15 to 0.08). The green tea trials were based on short durations (<3 months in half of the trials), similar to several trials included here in the non-diabetic and pre-diabetic strata, and eight trials in the T2DM stratum. Removal of these eight trials in the T2DM stratum did not change the outcome of metaanalysis, with a reduction of HbA1c highly significant (¡0.27%; SE: 0.07%; 95% CI: ¡0.40 to ¡0.14; P < 0.001). Since HbA1c% is a long-term predictor of diabetes complications, any effect should be measured using a marker that reflects a change due to exposure.
Only five trials were found that met the inclusion criteria for non-diabetic and pre-diabetic groups. Two trials included T2DM subjects and these studies were divided for the analysis. Although there were more trials that declared HbA1c% in their analysis, the reduction after treatment or baseline was not mentioned. This reduced the number of trials included in the metaanalysis. Long-term, high quality RCTs are needed to verify the effects of polyphenols' intervention on HbA1c in non-diabetic and pre-diabetic subjects. Moreover, few of the trials included assessed HbA1c concentrations as their primary outcome, so sample sizes were not estimated for this outcome. An increased risk of coronary heart disease, ischemic stroke, and death has been observed even in the normal concentrations of HbA1c (Selvin et al., 2004) . The risks of microvascular events can progressively lower down for pre-diabetic individuals when HbA1c concentrations yield 6.5% (Zoungas et al., 2012) . Therefore, The trials included in this meta-analysis had a variety of polyphenol sources, dosage, presentation, duration of RCTs, differences in ethnicity, health condition, heterogeneous groups of subjects, and, for T2DM, glucose control level medication, which could have led to a bias among the trials, and therefore to the heterogeneity observed. For instance, in the T2DM trials, polyphenols were presented principally as capsules or extracts, while in the non-diabetic and pre-diabetic trials, the main source of polyphenol was food.
Not all polyphenols have the same properties, and relatively few have been fully assessed for their bioavailability and metabolic fate after ingestion, or for effect of food matrix and background dietary compositions (Crozier et al., 2009 ). This heterogeneity inherent to nutritional interventions probably introduces substantial variance in outcomes and should be taken in consideration (even for the T2DM stratum) when interpreting the results and drawing conclusions. In fact, polyphenol urinary concentration or other biomarkers of intake should be measured to indicate compliance and to demonstrate that an increase of polyphenol has been achieved during the intervention, and so forth, relate the change in HbA1c concentration to an increase in polyphenols intake. In this case, only seven (Kudolo et al., 2005; Pan et al., 2007; Balzer et al., 2008; Fenercioglu et al., 2010; Curtis et al., 2012; Vinson et al., 2012; Toolsee et al., 2013) of the trials included in the meta-analysis included polyphenol metabolite analysis or antioxidant capacity assay.
A dose-response effect between polyphenol and HbA1c was not included in the meta-analysis given the variability of trials. Dietary approaches included in this meta-analysis supplemented the diets with 28 to 1500 mg/day polyphenols. Polyphenol rich extracts had a more marked effect in reducing HbA1c among the trials. The isoflavonoid extract doses (125 mg/d) used in the supplements can be achieved with the ingestion of soy products (Song et al., 1998; Rau De Almeida Callou et al., 2010) . Similarly, a daily intake of 1-3 g of cinnamon (27 mg/d of coumarin) can be feasible to reduce HbA1c concentrations (He et al., 2005; Shan et al., 2005) . On the other hand, resveratrol dose (250 mg/d) could be achieved with extracts, since red wine, with the highest resveratrol content, presents around 3 mg/ 100 mL (Lamikanra et al., 1996) . In terms of physiological relevance, a strict and well-designed dietary intervention should be able to deliver similar doses of certain polyphenols as those obtained by supplements. It is however still unclear how the food matrix and downstream cascade of physiological events associated with food (and meal) structure can affect the biological activity of food bioactives, including polyphenols. A western diet is able to deliver between 109 mg and 313 mg of polyphenol per day, 820 mg and 1.3 g for a Mediterranean diet (Sowers et al., 2006; Dilis et al., 2010; Touvier et al., 2013; Tresserra-Rimbau et al., 2013; Zamora-Ros et al., 2013) .
In summary, the results of the meta-analysis showed that polyphenol supplementation is associated with a significant reduction in HbA1c (%) in the total population. This effect is more profound in subjects with T2DM, whereas in pre-and non-diabetic subjects, the relatively small number of published trials, the low study quality, and the small effect size of the interventions did not allow for the detection of a significant effect. In spite of small effect size of the polyphenol supplementation trials, the meta-analysis shows a good potential of such intervention in terms of clinical and public health significance that needs further investigation. Importantly, the doses supplemented are achievable through dietary modification and offer a large range of opportunities for intervention. More long-term controlled trials of high quality are needed, especially in populations free (but at risk) of diabetes (e.g. those with overweight, high blood pressure, or impaired glucose tolerance).
